Innovative Reformulation Hyloris specializes in reformulating and repurposing existing medications using the 505(b)(2) pathway, enabling faster market entry and cost efficiencies. Sales opportunities exist in partnering to license or co-develop reformulated drugs that address unmet medical needs across various therapeutic areas.

Active Product Pipeline The company has two commercial-stage products, Sotalol IV and Maxigesic IV, with ongoing clinical trials including Phase 3 for Tranexamic Acid Oral Rinse. This presents opportunities to promote complementary formulations or new indications to healthcare providers and payors.

Strategic Collaborations Recent partnerships with companies like RedHill Biopharma, AFT Pharmaceuticals, and Pleco Therapeutics highlight market interest in Hyloris' innovative approach. These collaborations open avenues for joint ventures, licensing deals, and expansion into new markets or therapeutic areas.

Regional Funding & Support Support from the Walloon Region with non-dilutive funding of EUR 1 million underscores regional backing and growth potential. This funding can facilitate the commercialization of new formulations, providing a sales entry point for solutions aligned with regional healthcare priorities.

Focused Market Strategy Targeting healthcare sectors that benefit from reformulated drugs such as pain management, antiviral, and oral care provides sales prospects with physicians, clinics, and hospitals seeking innovative, effective alternatives to standard therapies, especially in post-operative and anticoagulant patient care.